Canaccord Genuity Maintains Buy on Mind Medicine, Lowers Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained its Buy rating on Mind Medicine (NASDAQ:MNMD) but has lowered the price target from $16 to $14.
September 16, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity has maintained its Buy rating on Mind Medicine but lowered the price target from $16 to $14, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in the stock, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100